Celgene Corporation CELG reiterated its '15 guidance of $8B in total revs & $8 in EPS, Deutsche Bank reports.
“The company sees $6-6.5B revs coming from hematology business,” Deutsche Bank writes. “Revlimid will contribute towards 70%-80% of hematology sales. Abraxane '15 sales are expected in the range of $1-1.2B. The remaining revs are expected to come from Apremilast sales.
“Celgene expects to achieve the total rev guidance even if Apremilast does not launch as it sees enough buffers in the existing product portfolio to reach to guidance levels.”
Celgene Corporation closed Monday at $59.78.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in